Impact of cocaine abuse on HIV pathogenesis
- PMID: 26539167
- PMCID: PMC4611962
- DOI: 10.3389/fmicb.2015.01111
Impact of cocaine abuse on HIV pathogenesis
Abstract
Over 1.2 million people in the United States are infected with the human immunodeficiency virus type 1 (HIV-1). Tremendous progress has been made over the past three decades on many fronts in the prevention and treatment of HIV-1 disease. However, HIV-1 infection is incurable and antiretroviral drugs continue to remain the only effective treatment option for HIV infected patients. Unfortunately, only three out of ten HIV-1 infected individuals in the US have the virus under control. Thus, majority of HIV-1 infected individuals in the US are either unaware of their infection status or not connected/retained to care or are non-adherent to antiretroviral therapy (ART). This national public health crisis, as well as the ongoing global HIV/AIDS pandemic, is further exacerbated by substance abuse, which serves as a powerful cofactor at every stage of HIV/AIDS including transmission, diagnosis, pathogenesis, and treatment. Clinical studies indicate that substance abuse may increase viral load, accelerate disease progression and worsen AIDS-related mortality even among ART-adherent patients. However, confirming a direct causal link between substance abuse and HIV/AIDS in human patients remains a highly challenging endeavor. In this review we will discuss the recent and past developments in clinical and basic science research on the effects of cocaine abuse on HIV-1 pathogenesis.
Keywords: AIDS; HIV; cocaine; drug use; pathogenesis.
Figures
References
-
- Anthony J. C., Vlahov D., Nelson K. E., Cohn S., Astemborski J., Solomon L. (1991). New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am. J. Epidemiol. 134, 1175–1189. - PubMed
Publication types
Grants and funding
- UL1 TR000445/TR/NCATS NIH HHS/United States
- R24 DA036420/DA/NIDA NIH HHS/United States
- R03 DA030896/DA/NIDA NIH HHS/United States
- T32 AI007281/AI/NIAID NIH HHS/United States
- U54 MD007593/MD/NIMHD NIH HHS/United States
- TL1 TR000447/TR/NCATS NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- K99 DA024558/DA/NIDA NIH HHS/United States
- T32 HL007737/HL/NHLBI NIH HHS/United States
- G12 MD007586/MD/NIMHD NIH HHS/United States
- R24 DA021471/DA/NIDA NIH HHS/United States
- R03 DA033892/DA/NIDA NIH HHS/United States
- TL1 RR024978/RR/NCRR NIH HHS/United States
- T32 HL007735/HL/NHLBI NIH HHS/United States
- R00 DA024558/DA/NIDA NIH HHS/United States
- U54 RR026140/RR/NCRR NIH HHS/United States
- R03 DA037779/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
